Elevated Glycolated Hemoglobin in Young People Predicts Likelihood of Diabetes or Cardiovascular Disease in Adulthood
By LabMedica International staff writers Posted on 19 Aug 2020 |
Model of the HbA1c molecule (image courtesy of Biologic Models)
A review of blood test results from more than 14,000 young people suggested that measurement of glycated hemoglobin (HbA1c) was a specific and useful nonfasting marker for identify high-risk youth who could benefit from lifestyle interventions to prevent diabetes and cardiovascular risk in adulthood.
The American Diabetes Association (ADA) has estimated that more than 34 million or roughly 10% of Americans have diabetes, and many of these cases are undiagnosed. Furthermore, obesity-associated type II diabetes is rapidly becoming more prevalent in children, due to the rise in obesity, poor diet, and sedentary lifestyles.
In this light, investigators at Johns Hopkins University (Baltimore, MD, USA) evaluated the performance of current clinical definitions of prediabetes and diabetes based on glycolated hemoglobin (HbA1c), fasting plasma glucose (FPG), either HbA1c or FPG, or both HbA1c and FPG (confirmatory definition) to identify youth at high cardiometabolic risk. For this study, the investigators reveiwed blood test data on 14,119 young people aged 10 to 19 from the U.S. National Health and Nutrition Examination Surveys ( NHANES) conducted between 1999 and 2016.
Results revealed that associations with cardiometabolic risk were consistently stronger and more specific for HbA1c-defined hyperglycemia (specificity = 98.6%; sensitivity = 4.0%) than FPG-defined hyperglycemia (specificity = 90.1%; sensitivity = 19.4%). Furthermore, 51% of subjects with HbA1c-defined hyperglycemia were obese compared to just 29% with hyperglycemia defined by the fasting glucose test.
"Our study demonstrates that HbA1c is a useful non-fasting test for identifying high-risk youth who could benefit from lifestyle interventions to prevent diabetes and cardiovascular disease later in life," said senior author Dr. Elizabeth Selvin, professor of epidemiology, at Johns Hopkins University. "Some pediatricians have already been using HbA1c, but there has not been sufficient guidance from pediatric organizations. I am hoping that these results will help inform and guide the use of this important screening tool in clinical practice."
The study was published in the August 10, 2020, online edition of the journal Pediatrics.
Related Links:
Johns Hopkins University
The American Diabetes Association (ADA) has estimated that more than 34 million or roughly 10% of Americans have diabetes, and many of these cases are undiagnosed. Furthermore, obesity-associated type II diabetes is rapidly becoming more prevalent in children, due to the rise in obesity, poor diet, and sedentary lifestyles.
In this light, investigators at Johns Hopkins University (Baltimore, MD, USA) evaluated the performance of current clinical definitions of prediabetes and diabetes based on glycolated hemoglobin (HbA1c), fasting plasma glucose (FPG), either HbA1c or FPG, or both HbA1c and FPG (confirmatory definition) to identify youth at high cardiometabolic risk. For this study, the investigators reveiwed blood test data on 14,119 young people aged 10 to 19 from the U.S. National Health and Nutrition Examination Surveys ( NHANES) conducted between 1999 and 2016.
Results revealed that associations with cardiometabolic risk were consistently stronger and more specific for HbA1c-defined hyperglycemia (specificity = 98.6%; sensitivity = 4.0%) than FPG-defined hyperglycemia (specificity = 90.1%; sensitivity = 19.4%). Furthermore, 51% of subjects with HbA1c-defined hyperglycemia were obese compared to just 29% with hyperglycemia defined by the fasting glucose test.
"Our study demonstrates that HbA1c is a useful non-fasting test for identifying high-risk youth who could benefit from lifestyle interventions to prevent diabetes and cardiovascular disease later in life," said senior author Dr. Elizabeth Selvin, professor of epidemiology, at Johns Hopkins University. "Some pediatricians have already been using HbA1c, but there has not been sufficient guidance from pediatric organizations. I am hoping that these results will help inform and guide the use of this important screening tool in clinical practice."
The study was published in the August 10, 2020, online edition of the journal Pediatrics.
Related Links:
Johns Hopkins University
Latest Molecular Diagnostics News
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders